Akademik Veri Yönetim Sistemi
Retina-Vitreus, cilt.19, sa.4, ss.231-236, 2011 (Scopus)
Purpose: To evaluate the efficacy of intravitreal ranibizumab injection in choroidal neovascularization (CNV) secondary to causes other than age-related macular degeneration (AMD). Materials and Methods: We retrospectively reviewed the medical records of 23 eyes of 19 patients who were diagnosed with CNV secondary to causes other than AMD and treated with intravitreal ranibizumab injection during May 2006 and June 2010 at Ankara University Department of Ophthalmology. Ranibizumab injections were performed at intervals of 4 weeks as monotherapy and Best Corrected Visual Acuity (BCVA), fundus examination, optical coherence tomography (OCT) and fundus angiography (FA) findings were retrospectively reviewed at each visit. Results: 10 patients were male (52.6%), 9 were female (47.4%). The mean age was 46.37± 18.7 (21-84). Mean follow-up was 16.8± 7.9 (2-34) months. 6 eyes (26.10%) had degenerative myopia, 5 eyes (21.70%) had angioid streaks, 4 eyes (%17.40) had Best vitelliform dystrophy and 8 eyes (34.80%) had idiopathic CNV. The mean number of injections were 4± 2.8 in eyes with degenerative myopia, 2.8± 0.44 in eyes with angioid streaks, 2.75± 1.25 in eyes with Best vitelliform dystrophy and 2.12± 0.99 in eyes with idiopathic CNV. The mean BCVA before and after injection were 1.45± 0.73 and 1.00± 0.50 logMAR (p> 0.05) in eyes with degenerative myopia, 0.44± 0.31 and 0.20 ± 0.18 logMAR (p> 0.05) in eyes with angioid streaks, 0.92± 0.71 and 0.22± 0.26 logMAR (p> 0.05) in eyes with Best vitelliform dystrophy, 0.47± 0.36 and 0.22± 0.40 (p< 0.0125) logMAR in eyes with idiopathic CNV. After the treatment, the numerical increase in BCVA levels were found in all diagnostic groups, but this increase was statistically significant only in eyes with idiopathic CNV group due to high number of cases compared with other groups. Subretinal/intraretinal fluid decreased or disappeared on OCT scans in accordance with the increase in BVCA. Conclusion: Short term results of intravitreal ranibizumab injection for CNV from causes other than AMD seem to be a safe and effective method but larger series, longer term studies are needed to determine the effectiveness of the long-term.